Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics Inc. (NYSE American: OGEN) is a publicly-traded biopharmaceutical company specializing in innovative, proprietary technologies aimed at improving human health. Based in Sarasota, Florida, Oragenics is renowned for its cutting-edge research and development in the fields of neurology and infectious diseases. The company’s core business revolves around the development of novel pharmaceutical treatments, including nasal delivery medications, which promise significant advancements in therapeutic efficacy and patient outcomes.
Oragenics’ flagship product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid. Designed to cross the blood-brain barrier effectively, ONP-002 targets mild Traumatic Brain Injury (mTBI), commonly known as concussion. The drug reduces swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. This revolutionary approach positions ONP-002 as a potential game-changer in treating brain injuries.
In addition to ONP-002, Oragenics boasts a diverse product pipeline, including therapies targeting Niemann-Pick Disease Type C (NPC) and other infectious diseases. The company is also recognized for its ProBiora3 technology, which is the foundation of products like evoraplus™—a unique probiotic mint that promotes oral health by supporting gums, freshening breath, and whitening teeth.
Recent achievements highlight Oragenics' relentless pursuit of excellence. The company is preparing to initiate a Phase II clinical trial for ONP-002, with advancements in drug formulation aimed at optimizing intranasal delivery. Collaborating with Avance Clinical Pty Ltd, Oragenics is focused on conducting this trial in emergency departments at level one trauma centers, ensuring robust and well-structured studies.
The leadership team at Oragenics, led by President Michael Redmond and Chief Medical Officer Dr. James Kelly, emphasizes the importance of partnerships and advanced research. Their dedication is reflected in Oragenics' preclinical studies, which have shown significant improvements in molecular and behavioral outcomes following brain injury. The company's innovative approach to intranasal delivery as nanoparticles has further enhanced brain exposure and metabolism.
Oragenics' commitment to addressing unmet medical needs, such as concussions—which affect millions globally each year—has positioned the company as a pivotal player in the biopharmaceutical industry. Through continuous innovation and strategic collaborations, Oragenics aims to provide effective treatments for neurological disorders and improve patient outcomes worldwide.
For more information, visit www.oragenics.com.
Oragenics, Inc. (NYSE American: OGEN) announced the adjournment of its Annual Meeting of Shareholders originally scheduled for November 22, 2021, due to insufficient quorum. The meeting will reconvene on January 25, 2022, at 4:00 p.m. ET, to allow more time for shareholders to vote on proposals detailed in the proxy statement filed with the SEC on October 13, 2021. Currently, only 40% of shares are represented by proxy. Shareholders are encouraged to vote by January 24, 2022, at 11:59 p.m. ET. The company is enlisting Alliance Advisors to help secure the necessary votes.
Oragenics (NYSE American: OGEN) has been awarded a $250,000 small business innovation research grant for its lantibiotics research. The funding will support the development of novel antibiotics addressing ESKAPE pathogens, which are increasingly resistant to existing treatments. The grant, part of the National Institutes of Health's initiative, emerges amidst rising antibiotic resistance and aims to enhance the company’s R&D capabilities in collaboration with Florida International University. Executive Chairman Frederick W. Telling expressed optimism about the potential of lantibiotics in combating life-threatening infections.
Oragenics, Inc. (NYSE American: OGEN) has launched a study to evaluate the immunogenicity and viral load reduction of its SARS-CoV-2 vaccine candidate, Terra CoV-2, using novel adjuvants for both intranasal and intramuscular formulations. The hamster challenge study aims to assess cross-neutralization against COVID-19 variants, with results expected in November. These findings will contribute to the Investigational New Drug filing with the FDA, anticipated in Q1 2022, to advance into human clinical trials.
Oragenics, Inc. (NYSE American: OGEN) announces promising results in its COVID-19 vaccine development, utilizing a stabilized pre-fusion spike protein trimer that generates neutralizing antibodies in mice. Collaborating with NIH, the company is advancing candidates for a hamster viral challenge study, set to begin this month. OGEN plans to submit an IND application for its Terra CoV-2 vaccine in Q1 2022, confident in the immunogenicity of its novel adjuvants. The firm aims to improve vaccine development speed, addressing potential COVID-19 variants amidst ongoing public health challenges.
Oragenics, Inc. (AMEX: OGEN) announced the adjournment of its reconvened annual meeting of shareholders on August 23, 2021, due to a lack of quorum. A new date for the annual meeting will be established, along with a new record date, as the previous one from May 5, 2021 is no longer valid. Oragenics focuses on combating infectious diseases, with its lead product, Terra CoV-2, aimed at preventing COVID-19 and its variants.
Oragenics, Inc. (NYSE American: OGEN) has entered a licensing agreement with the National Research Council of Canada to develop next-generation vaccines against SARS-CoV-2 and its variants. The collaboration leverages NRC technologies, enhancing the speed of cell line production for spike protein antigens from six months to six to eight weeks. The company has initiated preclinical studies and aims to advance vaccine candidates rapidly. This strategy may position Oragenics competitively against existing vaccines, particularly with additional options like intranasal administration.
Oragenics, Inc. (NYSE American: OGEN) has announced that its annual shareholder meeting, convened on June 30, 2021, was adjourned due to a lack of quorum. The meeting is rescheduled for August 23, 2021, at 4:00 p.m. The Company continues to solicit votes to meet the quorum requirement of a majority of shares. Currently, only 40% of the shares are represented by proxy. Shareholders of record as of May 5, 2021, are urged to vote by August 22, 2021. If quorum is not reached, further adjournment may incur additional costs.
Oragenics (NYSE American: OGEN) affirms its commitment to advancing its business strategy following the resignation of CEO Alan Joslyn. Executive Chairman Frederick W. Telling will take a more active management role. The company is focused on developing the Terra CoV-2 vaccine to combat COVID-19 and antibiotic resistance through its lantibiotics program. Oragenics has a strong leadership team and has recently raised nearly $22 million to support its initiatives, which positions it to continue operations well into 2022.
Oragenics, Inc. (NYSE American: OGEN) announced the resignation of Dr. Alan Joslyn as CEO and President, effective May 2, 2021. Dr. Frederick Telling transitions to Executive Chairman, while CFO Mr. Sullivan takes on the role of interim principal executive officer. The Board will guide the company in the interim as they seek a new CEO to lead the Terra CoV-2 vaccine development. Oragenics focuses on creating a vaccine to combat COVID-19 and developing new antibiotics. The company expresses gratitude for Dr. Joslyn's contributions and remains committed to future growth.
Oragenics, Inc. (NYSE American: OGEN) has entered into a material transfer agreement with Biodextris Inc. regarding the use of three intranasal mucosal adjuvants for its Terra CoV-2 vaccine against COVID-19. The adjuvants—BDX100, BDX300, and BDX301—aim to enhance immune response and manufacturing efficiency. This collaboration will facilitate preclinical studies essential for FDA Investigational New Drug applications and potential clinical trials. Oragenics' vaccine offers advantages like refrigerated storage, aiming to address ongoing COVID-19 vaccination needs.
FAQ
What is the current stock price of Oragenics (OGEN)?
What is the market cap of Oragenics (OGEN)?
What does Oragenics Inc. specialize in?
What is ONP-002?
What is the ProBiora3 technology?
What recent achievements has Oragenics made?
Who are key leaders at Oragenics?
What is the significance of intranasal delivery for ONP-002?
How does ONP-002 impact brain injury treatment?
What are the potential benefits of ONP-002?
What are common causes of concussions that ONP-002 aims to treat?
Where can I find more information about Oragenics?
